alk in 5

ALK5-IN-30 (EX-07) is a potent inhibitor of ALK, demonstrating inhibitory effects on ALK5 and TGFβ-R1 with IC50 values of less than 10 nM.

ALK5-IN-6 is a potent inhibitor of ALK5 with potential applications for TGF-β-related diseases and conditions, including tumors, inflammatory diseases, fibrotic diseases, and autoimmune diseases. Transforming growth factor β (TGF-β) is a multifunctional cytokine that regulates cell proliferation, differentiation, and apoptosis through a complex receptor signaling pathway on the cell surface in an autocrine, paracrine, and endocrine manner.

ALK5-IN-8 is a highly effective inhibitor of TGFβRI (ALK5). It hinders the phosphorylation of ALK5 on downstream signaling proteins (Smad2 or Smad3) by obstructing the interaction between TGFβRI and ligands. Consequently, it disrupts or prevents TGF-β signaling. ALK5-IN-8 shows promise in the study of diverse diseases associated with ALK5-mediated pathways[1].

ALK5-IN-29 is a selective inhibitor of activin receptor-like kinase (ALK).ALK5-IN-29 inhibits activin receptor-like kinase activity (IC50 ≤ 10 nM).AALK5-IN-29 inhibits tumour growth and can be used in the study of proliferative diseases such as cancer.

ALK5-IN-9 is a potent, orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation (IC50: 25 nM) and inhibits NIH3T3 cell activity (IC50: 74.6 nM). ALK5-IN-9 has shown research potential in cancer diseases.

ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].

ALK5-IN-34 is a selective, orally active inhibitor of activin receptor-like kinase (ALK), which inhibits the activity of activin receptor-like kinase (IC50 ≤ 10 nM) and also inhibits tumour growth.

ALK5-IN-7 is an effective inhibitor of ALK5. Transforming growth factor β (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation, and apoptosis through autocrine, paracrine, and endocrine pathways using complex receptor signaling pathways on the cell surface. ALK5-IN-7 has the potential to perform research on TGF-β-related diseases and conditions (including but not limited to tumor, fibrosis, inflammatory diseases, autoimmune diseases, etc.).

ALK5-IN-26 (EX-22) is an ALK (Activin receptor-like kinase) inhibitor with an IC50 ≤ 1 nM for ALK5.

Trk-IN-7 (compound I-6) is a highly potent TRK inhibitor, with IC50 values of 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. It also shows significant inhibition of EML4-ALK (IC50 <15 nM) and ALK mutations G1202R, C1156Y, R1275Q, F1174L, L1197M, and G1269A (IC50 = 5-50 nM) [1].

TGFβRI-IN-2 is a selective, potent and orally active inhibitor of (Activin-Like Kinase 5) ALK 5(pIC50 and pEC50 values of 7.6 and 6.63, respectively).

CEP-14513 is a potent ALK inhibitor. CEP-14513 displayed potent ALK inhibitory activity in both in vitro enzymatic assay (IC50 = 5 nM) and cell-based assays of ALK tyrosine phosphorylation (IC50 = 30 nM).